A recent op-ed notes that the California Drug Price Relief Act is a distraction from anti-fraud measures. Backing California’s already successful efforts to curb fraud in Medi-Cal is a more promising way to control costs than targeting the pharmaceutical industry. Read more on the issue here.
Last Updated on May 7, 2020 by Aimed Alliance
